Treatment Options for Stage IVA Esophageal Cancer

Systemic Chemotherapy Approach

The European Society for Medical Oncology recommends platinum-fluoropyrimidine combinations as first-line therapy for patients with good performance status and adenocarcinoma 1, 2
Oxaliplatin/fluoropyrimidine combinations offer equivalent efficacy to cisplatin/5-FU with improved tolerability in patients with adenocarcinoma 2
Taxanes are recommended in first-line combinations or as second-line monotherapy for patients with adenocarcinoma 2
For squamous cell carcinoma, the evidence for palliative chemotherapy is weaker than for adenocarcinoma, and cisplatin-based combinations show increased response rates but no survival benefit over monotherapy 2

Single-dose brachytherapy (12 Gy) is the preferred intervention for dysphagia relief because it provides better long-term symptom control with fewer complications than metal stent placement 1, 2, 3
Brachytherapy offers superior long-term durability compared to stenting for dysphagia relief 1, 2, 3

For adenocarcinoma of the esophagogastric junction, HER2 testing is mandatory, and if HER2-positive, trastuzumab should be added to cisplatin/fluoropyrimidine combination 4

Chemotherapy is indicated only for selected patients with good performance status, and for adenocarcinoma patients with good performance status, chemotherapy should be strongly considered 1, 2
For poor performance status patients, best supportive care may be more appropriate than aggressive chemotherapy 2

Aggressive chemotherapy should not be used in poor performance status patients, as the toxicity will outweigh any potential benefit 2
Stents should not be placed as first-line for dysphagia when brachytherapy is available, as long-term outcomes are inferior 1, 2

Regular surveillance imaging does not improve outcomes in stage IV disease, and follow-up should focus on symptom management, nutritional support, and psychosocial needs 1, 2